How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hyperparathyroidism-secondary-to-chronic-renal-failure.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hyperparathyroidism Secondary to Chronic Renal Failure — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperparathyroidism Secondary to Chronic Renal Failure (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hyperparathyroidism Secondary to Chronic Renal Failure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zemplar	PARICALCITOL	AbbVie	Vitamin D2 Analog [EPC]	Vitamin D3 receptor	1998-01-01
Calcijex	CALCITRIOL	Esjay Pharma	Vitamin D3 Analog [EPC]	Vitamin D3 receptor	1978-01-01
Zemplar	Zemplar	Danderyd Hospital		Vitamin D3 receptor
Rocaltrol	Rocaltrol	Shandong University		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 1 drug in Hyperparathyroidism Secondary to Chronic Renal Failure
Danderyd Hospital · 1 drug in Hyperparathyroidism Secondary to Chronic Renal Failure
Esjay Pharma · 1 drug in Hyperparathyroidism Secondary to Chronic Renal Failure
Shandong University · 1 drug in Hyperparathyroidism Secondary to Chronic Renal Failure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hyperparathyroidism Secondary to Chronic Renal Failure:

Cite this brief

Drug Landscape (2026). Hyperparathyroidism Secondary to Chronic Renal Failure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hyperparathyroidism-secondary-to-chronic-renal-failure. Accessed 2026-06-10.

Hyperparathyroidism Secondary to Chronic Renal Failure full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing